Form 4: Scholar Rock COO & CFO Myles Executes Stock Option and Sells Shares Under 10b5-1 Plan

Edward H. Myles, COO & CFO of Scholar Rock Holding Corp, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On October 8, 2024, Edward H. Myles, the COO & CFO of Scholar Rock Holding Corp, executed a stock option to purchase 37,187 shares at $10 per share.
• Simultaneously, Myles sold 37,187 shares of common stock at a weighted average price of $34.8955, with prices ranging from $34.50 to $35.32.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on March 7, 2024.
• Following these transactions, Myles directly owns 161,088 shares of Scholar Rock Holding Corp.
• Myles also holds options to purchase 47,813 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, and there's no indication of unusual activity or concern.

Positives

• The use of a 10b5-1 trading plan suggests that the transactions were pre-planned and not based on insider information at the time of the trades.

Negatives

• The sale of shares by a high-ranking executive could be interpreted negatively by some investors, although the use of a 10b5-1 plan mitigates this concern.

Risks

• While the 10b5-1 plan provides a framework for regular transactions, significant changes in the executive's holdings could still raise concerns among investors if not clearly communicated.

Industry Context

Form 4 filings are a routine part of the financial markets, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units, which vest over time to align executive interests with shareholder value.
• Sales under 10b5-1 plans are a common practice among executives at publicly traded companies, including those in the biotechnology sector like Amgen, Biogen, and Gilead Sciences, to manage their personal finances while avoiding insider trading concerns.
• The vesting schedule of the options, in sixteen quarterly installments, is a typical arrangement to incentivize long-term commitment.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the change in the number of outstanding shares, but the effect is likely minimal given the relatively small volume of shares involved.

Key Dates